Q-omics provides the consensus-scored MIRLET7G profile across patient tissues and cancer cell-line models. MIRLET7G expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, MIRLET7G is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, MIRLET7G RNA expression shows 11,121 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight PAAD, BRCA, and DLBC as cancer lineages where MIRLET7G shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIRLET7G — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIRLET7G survival associations across molecular data types. MIRLET7G RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIRLET7G RNA expression–survival associations across cancer types. High MIRLET7G expression shows unfavorable associations in UVM, UCS, READ, COAD and THCA, but favorable associations in PAAD. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for MIRLET7G RNA expression.
This table summarizes MIRLET7G tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIRLET7G. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIRLET7G shows lower tumor expression in BRCA and LUSC and higher tumor expression in STAD and KIRC. The BRCA box plot shows higher MIRLET7G RNA expression in normal versus tumor tissue (log2 FC = −0.491, t-test p < 0.001).
This table shows molecular features associated with MIRLET7G in patient tissues and cancer cell lines. In patient samples, MIRLET7G shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
